3-Fluoro-PCP, also known as 3′-F-PCP or 3F-PCP, is a synthetic designer drug belonging to the arylcyclohexylamine family. It is recognized for its dissociative effects, which can lead to altered perceptions and a sense of detachment from reality. This compound was initially discovered in Slovenia in October 2020 and was subject to legal restrictions in Hungary in April 2021.

IUPAC name
CAS Number89156-99-0 
1049718-37-7 (hydrochloride)
PubChem CID398433
CompTox Dashboard (EPA)DTXSID90327970
Chemical and physical data
Molar mass261.384 g·mol−1


1. What is 3-Fluoro-PCP (3′-F-PCP or 3F-PCP)?

  • 3-Fluoro-PCP is a synthetic designer drug classified within the arylcyclohexylamine family. It is known for its dissociative effects, which can lead to altered perceptions and a sense of detachment from reality.

2. How is 3F-PCP typically used?

  • 3F-PCP is often used for recreational purposes. It can be ingested orally, inhaled, or insufflated (snorted). The method of use may vary among individuals.

3. What are the effects of 3F-PCP?

  • The effects of 3F-PCP are characterized by dissociation, altered perception of reality, and a sense of detachment from one’s surroundings.

4. Is 3F-PCP legal?

  • The legal status of 3F-PCP may vary by country and region. As of April 2021, it was made illegal in Hungary. Users should be aware of the laws in their specific area regarding the possession and use of this substance.

5. Is 3F-PCP safe to use?

  • The safety of using 3F-PCP is a subject of concern, as its long-term effects and potential risks are not well-documented. Like many designer drugs, there can be health risks associated with use, including unknown purity and possible adverse reactions.

6. What are the risks and side effects of using 3F-PCP?

  • Common side effects may include nausea, disorientation, hallucinations, and impaired motor skills. Overdosing can lead to more severe symptoms such as anxiety, confusion, and potentially life-threatening conditions.

7. Can 3F-PCP be addictive?

  • There is a potential for psychological dependence with repeated use, but it is not considered highly physically addictive like some other substances.

8. How can I reduce the risks associated with 3F-PCP use?

  • If you choose to use 3F-PCP, it’s essential to start with a low dose, be in a safe environment, and have someone you trust present. Avoid mixing it with other substances and be aware of its potential adverse effects.

9. Is there a safe or recommended dosage for 3F-PCP?

  • The dosage can vary based on an individual’s tolerance and experience. It’s crucial to begin with a low dose and monitor how your body reacts before considering more.

10. Where can I find help or support for 3F-PCP-related issues?

  • If you or someone you know is struggling with substance use or addiction, it’s essential to seek professional help. Reach out to addiction treatment centers or healthcare providers for guidance and support.

11. Are there any medical or therapeutic uses for 3F-PCP?

  • 3F-PCP is not approved for medical use and should not be considered a substitute for prescribed medications or treatments.

Please note that this information is for informational purposes only, and the use of designer drugs like 3F-PCP carries risks and legal implications. Always prioritize your health and safety and be aware of the laws in your area.


  1. In January 1984, Cone EJ, McQuinn RL, and Shannon HE delved into “Structure-activity relationship studies of phencyclidine derivatives in rats.” Their research was published in The Journal of Pharmacology and Experimental Therapeutics, Volume 228, and it provided valuable insights into the effects of phencyclidine derivatives on rats. You can find this study with the PMID: 6694098.
  2. Ogunbadeniyi AM and Adejare A conducted research in 2002 focusing on the “Syntheses of fluorinated phencyclidine analogs.” This work was published in the Journal of Fluorine Chemistry, Volume 114, and is accessible via DOI: 10.1016/S0022-1139(01)00565-6. It explored the synthesis of phencyclidine analogs with fluorine substitutions.
  3. Catalani V, Arillotta D, Corkery JM, Guirguis A, Vento A, and Schifano F carried out a web-based investigation in 2020 titled “Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach.” This research, published in Frontiers in Psychiatry, Volume 11, can be accessed via DOI: 10.3389/fpsyt.2020.632405 and is also available on PMC with reference number 7900492 and PMID: 33633599.
  4. The National Forensic Laboratory in Slovenia produced an analytical report on “3F-PCP (C17H24FN),” specifically identified as “1-(1-(3-fluorophenyl)cyclohexyl)piperidine.” This report offers critical information about this psychoactive substance.
  5. An “Amendment of Minister for Human Capacities Decree No 55/2014 of 30 December 2014 on substances or groups of compounds classified as new psychoactive substances, 2021/225/HU” was issued. This amendment plays a vital role in regulating substances and compounds classified as new psychoactive substances in Hungary.

Leave a Comment

Your email address will not be published. Required fields are marked *